Background
Heart failure (HF) is a common and disabling syndrome. The incidence of HF is stable in industrialized countries, but its prevalence continues to increase, especially due to the ageing of the population. The incidence of HF is currently estimated to be between 5 and 10 per 1000 subject-years, depending on the cohorts studied; the prevalence is estimated to be between 1% and 3% in industrialized countries [1, 2] . The incidence and prevalence of HF markedly increase with age. For example, the Framingham study reported a prevalence of clinical HF of 0.8% in subjects aged 50-59 years and of 9.1% in those aged 80-89 years in 1993 [3] . The mortality of patients with HF has decreased over the past two decades, but remains high, with a standardized mortality rate in Europe of 32.6/100,000 in 2008 [4] .
HF accounts for 1-2% of all healthcare expenditure and represents the leading cause of hospitalization after the age of 65 years in industrialized countries [2, 5] . This syndrome is characterized by a high rate of hospitalizations, especially for acute decompensation. In France, among all patients hospitalized for HF in 2008, 7.5% died during their hospitalization and 21% were readmitted for HF during the same year [6] . A high readmission rate is observed during the 30 days after discharge; for example, 5.6% of veterans in the USA were readmitted for a diagnosis of HF and 22% for all diagnoses combined between 2002 and 2006 [7] . Sixty-one percent of patients hospitalized for HF in the USA presented at least one factor of decompensation [8] . Based on these findings, disease management programmes before and after hospital discharge, comprising healthcare organization, patient education, training of healthcare professionals and/or home surveillance, have been demonstrated to be effective in many trials and have consequently been included in guidelines [9] [10] [11] .
This study was designed to estimate the incidence and describe the clinical characteristics, treatment and 30-day outcome of patients presenting a first hospitalization for HF in France among national health insurance general scheme beneficiaries, representing 77% of the French population.
Methods

Information system and population
In France, the Système National d'Information InterRégimes de l'Assurance Maladie (SNIIRAM; French national inter-regime health insurance information system) comprises an individual and anonymous database concerning the beneficiaries of the various schemes. The database comprehensively records all outpatient prescriptions, services and procedures performed and reimbursed, together with their dates, with historical data limited to a period of 3 years plus the current year. Medications are identified according to Anatomical Therapeutic Classification Code, laboratory tests are identified from the French National Laboratory Test Coding Table and the procedures performed on an outpatient basis or in private institutions are identified according to the Classification Commune des Actes Médicaux (French medical classification for clinical procedures). The SNIIRAM does not contain any clinical information concerning results related to prescriptions or examinations. Nevertheless, it indicates the presence of any 'affections de longue durée' (ALD; chronic diseases), such as cardiovascular diseases, which are eligible for 100% reimbursement of healthcare expenditure after application by the attending physician and approval by the national health insurance consultant physician. These chronic diseases are coded according to the International Classification of Diseases (ICD 10). An anonymous unique identification number for each subject links this information to data collected by the Programme de Médicalisation des Systèmes d'Information (national hospital discharge database) in healthcare institutions. During the patient's stay, principal diagnoses (PDs), related diagnoses and associated diagnoses (ADs) are coded according to ICD 10 and the procedures performed are coded according to the Classification Commune des Actes Médicaux. In 2009, the national health insurance general scheme covered about 77% of the 64 million inhabitants in France, excluding the 13% covered by local mutualist sections (SLM: students, civil servants, etc.). One of the reasons for limiting the study to this population was the availability of vital status and date of death from the National Institute for Statistics and Economic Studies (INSEE). The rest of the French population is covered by the Mutualité Sociale Agricole, the Régime Social des Indépendants and other specific health insurance schemes.
This study was based on the subpopulation covered by the national health insurance general scheme because, at the present time, the patient's survival status is not precisely indicated in the SNIIRAM for the other health insurance schemes. The first hospitalization in 2009 with a PD of HF (ICD code I50 heart failure) was selected to identify eligible patients. Hospitalizations with the following PDs were not included: I11.0 hypertensive heart disease; I13.0 hypertensive heart and renal disease with (congestive) heart failure; I13.2 hypertensive heart and renal disease with (congestive) heart failure and renal failure; I13.9 hypertensive heart and renal disease, unspecified; K76.1 chronic passive congestion of liver; and J81 pulmonary oedema. Eligible patients hospitalized with a PD of HF between 2006 and 2008, an AD of HF in 2008 and/or ALD chronic disease status for HF before the index hospitalization were then excluded.
Definitions
The search for co-morbidities before the first hospitalization for HF took into account the presence of specific chronic diseases and the presence, during the previous year, of at least one hospitalization with a PD for hypertensive disease, coronary heart disease or cardiomyopathy. 'Tumour' chronic diseases were subdivided into tumours of haematopoietic tissues (ICD codes C81 to C96) and breast tumours (C50).
Data reported for the index hospitalization for HF included the number and types of medical units coded in the Programme de Médicalisation des Systèmes d'Information (intensive care, cardiac intensive care, palliative care, etc.). Readmissions were taken into account whatever the reason for admission, when they occurred between 7 and 30 days after discharge, in order to eliminate early transfers. Readmissions were classified according to the presence of a PD or AD code for HF. Drug treatments were identified by the presence of at least three reimbursements during the 6 months preceding the index hospitalization and by a single reimbursement during the 30 days following discharge. Beta-blockers with marketing authorization for the treatment of HF were grouped under the term 'specific'. Potassium-sparing diuretics combined with another diuretic in fixed-combination medicinal products were distinguished. Patients with no medicinal product reimbursement, all classes combined, during the 6 months preceding and/or the 30 days following hospitalization (mainly patients living in an institution directly dispensing medicinal products) were excluded from the comparative study of treatments before and after hospitalization.
Echocardiographs were identified by the presence of a specific code, whether they were performed in hospital or on an outpatient basis. Reimbursements for cardiology hospital outpatient and office visits were taken into account. Echocardiography was not systematically coded during a cardiology visit, as the levels of reimbursement may be similar for a visit with or without echocardiography. To compensate for this missing coding, a variable was constructed by combining the existence of at least one visit to the cardiologist or echocardiography.
Laboratory assays such as brain natriuretic peptide (BNP) could not be identified when they were performed in a public hospital, as they are not reimbursed individually.
Statistical analysis
The incidence of a first hospitalization for HF was calculated from all patients selected in 2009 divided by the number of individuals covered by the national health insurance general scheme, apart from SLM, at 31 December 2009, according to age and sex. Regional incidence rates were standardized for age and sex of the general scheme population.
The mortality rate was calculated during hospitalization, during the 30 days after admission and during the 30 days after discharge. Readmissions were expressed as patients with at least one readmission with a diagnosis of HF (as PD and PD or AD) or for all diagnoses combined.
Patient and management characteristics were studied among those patients still alive at 30 days and compared with those of all patients hospitalized. The frequencies of co-morbidities and the consumption of certain medicinal products were compared between these patients and the other subjects covered by the general scheme. A frequency ratio (relative risk [RR]) was calculated according to age for the two groups, with a 95% confidence interval. This ratio was also standardized for age and sex among subjects aged ≥ 55 years.
Statistical analyses were performed with SAS Enterprise Guide software, version 4.3 (SAS Institute Inc., Cary, NC, USA). 
Results
In
Incidence of first hospitalization for heart failure
The incidence of a first hospitalization for HF was 0.14% for the whole population (all ages combined) and 0.5% for patients aged ≥ 55 years ( Fig. 1) . This incidence increased considerably after the age of 70 years and was > 3% after the age of 90 years. Men presented a slightly higher incidence than women for all age groups considered (0.55% vs. 0.48% for patients aged ≥ 55 years). The age-and sex-standardized incidence according to region ranged between 0.11% and 0.18% (Fig. 2) ; it was higher in northern and north-western 
Outcome of hospitalized patients: death and readmissions
The hospital mortality rate was 6.4% (Table 1) . After standardization for age, this rate was slightly higher in men than in women (6.7% vs. 5.9%). The hospital mortality rate was 2.0% in patients aged < 55 years and 12.8% in patients aged ≥ 90 years. The mortality rate during the 30 days after discharge was 4.4%, without readmission for three-quarters of cases.
For patients surviving 30 days after discharge, at least one readmission (all diagnoses combined) was reported within 30 days for 18% of patients, with HF as the PD or AD in 9% of patients and HF as the PD in 5% of patients. Among patients readmitted, more than half had a cardiovascular disease as a PD, 12% had a factor influencing health status and contact with health services, 7% had a pulmonary disease and 4% had cancer. These readmission rates were higher among the youngest patients, especially for all-cause readmissions (21.7% for patients aged < 69 years and 12.7% for patients aged ≥ 90 years).
Pre-and post-hospitalization management of patients surviving 30 days after discharge
During the year preceding hospitalization, almost 46% of patients had undergone at least one echocardiography or had consulted a cardiologist, and at least one BNP assay had been reimbursed for 40% of them (Table 2 ). Eighteen percent of these patients were hospitalized in a private hospital, 21% in a university hospital (36% of patients aged < 55 years) and 61% in a public hospital. More than one quarter of patients were admitted to an intensive care unit or intermediate care unit (almost 40% of patients aged < 55 years). At the time of discharge, 79% of patients returned home and 21% were transferred to another unit, including a rehabilitation unit in one half of cases. Thirty days after discharge from hospital, 29% of patients had had at least one echocardiography or had attended a cardiology follow-up visit; 16% had had at least one BNP assay. No medicinal product reimbursement (all classes combined) was observed for 4.9% of patients during the year preceding hospitalization (5.2% for patients aged ≥ 90 years) and for 12.7% of patients during the 30 days after discharge (19.7% for patients aged ≥ 90 years).
Co-morbidities of patients surviving 30 days after discharge
These patients had a chronic disease recognized as an ALD in 71% of cases (Table 3) . Over the age of 55 years, the prevalence of chronic diseases was significantly higher for each form of cardiac disease, such as hypertension (RR 1.5), coronary heart disease (RR 1.7), arrhythmias (RR 2.0), valvular heart disease (RR 3.1), but also for other co-morbidities such as diabetes (RR 1.9), chronic respiratory failure (RR 1.6), chronic kidney disease (RR 2.2), chronic liver disease (RR 1.6) and psychiatric diseases (RR 1.2). Only Alzheimer's disease was less common among these patients (RR 0.6). These patients also more frequently presented ALD status for a tumour of haematopoietic tissue (RR 1.3) or breast cancer in women (RR 1.1). The RR values for these tumours and psychiatric illness and reimbursements for antipsychotic drugs were inversely correlated with patient age.
Drug treatments
A total of 53,168 patients (85% of survivors at 30 days) receiving at least one drug reimbursed 1 year before and 30 days after their first hospitalization for heart failure were selected for a comparison of the time-course of reimbursement of the main drugs ( Table 4 ). The use of betablockers increased after hospitalization from 40% to 54%; the use of specific beta-blockers increased from 14% to 31%. Although 60% of patients were being reimbursed at least a diuretic before their hospitalization, this frequency was 85% during the month following hospitalization (loop diuretic, increase from 46% to 81%; potassium-sparing diuretic, 10% to 17%; fixed combination of a potassium-sparing diuretic and another diuretic, 9% to 16%). Prescription of angiotensinconverting enzyme inhibitors (ACEIs) increased from 32% to 47%, while prescription of angiotensin II receptor blockers (ARBs) decreased from 26% to 21% and prescription of either an ACEI or an ARB increased from 56% to 67%. Prescription of a beta-blocker, diuretic and ACEI/ARB combination increased from 21% to 37% and prescription of a diuretic and ACEI/ARB combination increased from 21% to 23%. These frequencies and their variations after hospitalization were higher among the youngest patients. Younger patients more frequently benefited from an implantable cardioverter-defibrillator either during initial hospitalization or within the following month (3%). In patients with at least one medicinal product reimbursement during these two periods. ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker. a Age-standardized.
In addition, the use of potassium supplements increased from 13% to 32% after hospitalization and the use of class III antiarrhythmics increased from 15% to 24%. Increased use was also observed for oral anticoagulants (26% to 38%) and, to a lesser degree, platelet aggregation inhibitors (41% to 47%). The frequencies of use of antidiabetes treatments (26% to 25%) and lipid-lowering drugs (40% to 42%) remained relatively stable. The frequencies of use of non-steroidal and steroidal anti-inflammatory drugs were 7% and 5% before hospitalization and 4% and 6% after hospitalization, respectively.
Discussion
This study demonstrated a high incidence of first hospitalization for heart failure, especially in older patients, with a higher incidence in the northern regions, Corsica and Réu-nion. These patients, especially the youngest, presented a high co-morbidity rate compared with the other beneficiaries. The hospital mortality rate was 6%. The mortality rate during the 30 days following discharge was 4% and the allcause readmission rate was 18% (5% for HF) for patients who survived at least 30 days. The frequency of the beta-blocker, diuretic and ACEI/ARB combination during the 30 days after discharge was 37% overall, but 47% in the 55-69 years age group.
Epidemiology
Many epidemiological studies have been conducted on HF, but with various objectives, methodologies and sociodemographic and clinical inclusion criteria, making it difficult to compare their results. Higher incidences of HF have been reported in studies including all hospitalized patients (first hospitalization and rehospitalizations). In 2008, in France, the crude hospitalization rate for all patients was 0.23%, regardless of age, and 1.2% for patients aged ≥ 65 years (vs. 0.14% and 0.78% in our study on first hospitalizations for HF) [6] . In 1994, a hospitalization rate of 0.22% was reported in the French Lorraine region among all patients aged 20-80 years hospitalized presenting with clinical and echocardiographic criteria of advanced HF vs. 0.1% in this study for the same age group [12] . In Scotland, in 2000, a physician-based survey reported an outpatient incidence of HF of 0.2% among patients aged ≥ 45 years and 5.0% among patients aged ≥ 75 years (vs. 1.2% in the age group in our study) [13] . The first hospitalization rate for HF in Scotland in 2003 was 0.12% in men and 0.1% in women, close to the rates observed in our study [14] .
The regional disparity observed in the present study can be explained by variations in the distribution of risk factors, aetiology, diagnosis, clinical practice and indications for hospitalization. The national study on patients hospitalized for HF in 2008 also reported higher standardized hospitalization rates in northern regions of France [6] . The observed geographical distribution is similar to that of standardized regional hospitalization rates for myocardial infarction (higher in the northern, north-eastern and south-eastern regions) and stroke (higher in the northern and north-eastern regions and in Brittany) [15] . In 2010, the regional rates of treatment for hypertension or diabetes were also higher in the northern and north-eastern regions and in French overseas departments [16] .
The French national HF hospitalization study reported a growth in the crude hospitalization rate of 14.4% between 2002 and 2008, while the age-standardized rate slightly decreased (2.5%) [6] . Nevertheless, a significant increase in the hospitalization rate for HF was observed in women aged 45-54 years and in the hospitalization rate for myocardial infarction or stroke in women aged < 55 years [17, 18] . Studies in other countries, such as the USA, Canada and Scotland, have also reported a variable reduction in standardized hospitalization rates for HF [19] [20] [21] [22] . Among hospitalizations for HF, a growth in the relative proportion of systolic HF has also been reported in the USA (33% in 2005 and 39% in 2010) [22] .
Patient clinical characteristics
According to the mode of patient selection in this study, the hospitalization had to correspond to the first episode of decompensation in patients with previously known or unknown HF. However, 40% of the patients included in this study had had at least one BNP assay during the previous year, suggesting screening for chronic HF. Furthermore, almost 20% of patients were already being treated with a beta-blocker, diuretic and ACEI/ARB triple combination, suggesting that the diagnosis of HF had already been established.
Data in the literature indicate a proportion of 35-50% of diastolic HF, depending on the study and the age of the patients included, and this proportion increases with age [22, 23] . The two forms of HF cannot be distinguished in the present study due to the lack of clinical data. The relatively high mean age of patients in this study (77 years) would favour a higher proportion of diastolic HF. However, analysis of the ALD status for chronic diseases revealed a relatively high rate of diseases responsible for systolic HF, such as coronary heart disease (15%), diabetes (20%), arrhythmias (4.9%) and valvular heart disease (3.7%), but also severe hypertension (16.3%). Hospitalizations for coronary heart disease or cardiomyopathy were also more frequent among younger patients, who were more frequently hospitalized in university hospitals and in intensive care units due to differences in their clinical state or the clinical setting.
This study found a large proportion and a higher frequency of ALD chronic disease status for tumours of haematopoietic tissue among the youngest patients hospitalized for HF. Anthracyclines, used in the treatment of these tumours, have been reported to induce irreversible and sometimes late deleterious effects on cardiac function [24] . Adjuvant radiotherapy used in the 1980s for the treatment of breast cancers and, more recently, anthracyclines and trastuzumab have also been associated with the development of HF [25, 26] . However, these hypotheses could not be confirmed, as information on medicinal products in the SNIIRAM database is only available for the previous 3 years plus the current year.
A higher frequency of reimbursement for antipsychotics was also observed among the youngest patients hospitalized for HF, which may reflect risk behaviour, and a higher rate of cardiovascular risk factors, which can also be related to the use of antipsychotics, as some of them have been reported to be associated with hypotension, diabetes, arrhythmias, cardiomyopathies and sudden death [27] .
Treatment and management
Recent European guidelines concerning the treatment of systolic HF recommend first-line prescription of an ACEI, or an ARB when the ACEI is not well tolerated, followed by introduction of a beta-blocker. When the New York Heart Association score is still III or IV, it is recommended to add an aldosterone antagonist. If no improvement in left ventricular ejection fraction (< 35%) is observed, ivabradine can be used and, if still no improvement is obtained, placement of a cardiac resynchronization device and the use of digoxin. Diuretics are recommended to decrease symptoms or signs of congestion. No specific guidelines have been proposed for diastolic HF apart from symptomatic treatment and treatment of the underlying cardiovascular disease [10] . The French FUTURE study (2007) (2008) failed to demonstrate any significant differences in treatment frequencies on hospital discharge and at outpatient visits between patients with a left ventricular ejection fraction > 40% (44% of patients) or < 40% (56% of patients) [23] . Among the 1137 patients (mean age 72 years) followed by an office cardiologist, 83% were treated with an ACEI/ARB, 74% with beta-blockers, 31% with an aldosterone antagonist and 86% with a loop diuretic. The French IMPACT RECO study, in 2005, comprising 2000 patients (mean age 70 years) with New York Heart Association grade III and IV systolic HF followed by office cardiologists, reported fairly similar treatment frequencies: 68% for ACEIs and 30% for ARBs (i.e. 91% for an ACEI/ARB, 70% for beta-blockers [the highest increase], 35% for aldosterone antagonists and 85% for loop diuretics) [28] . The EuroHeart Failure Survey II in [2004] [2005] reported that 71% patients (mean age 70 years) were treated with an ACEI and 80% with an ACEI/ARB, 61% of patients were treated with a beta-blocker on discharge from hospital, 41% with an aldosterone antagonist and 90% with a diuretic [29] . In the present study, the frequencies of drug treatments 30 days after hospitalization were much lower than those reported above (beta-blocker 54%, ACEI 47%, ACEI/ARB 67%, diuretic 85%, aldosterone antagonist 33%). However, patients in our study were older (mean age 77 years) and probably more frequently presented contraindications to the use of drugs such as ACEIs and beta-blockers. This is illustrated by higher prescriptions of beta-blockers in more than 60% of cases and ACEIs/ARBs in about 75% of cases in patients aged < 80 years. Some treatments, such as beta-blockers, may also have been introduced subsequently, after the first month.
About 30% of patients attended a visit with a cardiologist or were assessed by echocardiography at the first month after hospitalization, with higher rates for the youngest patients, and at least one BNP assay was performed in 16% of cases. French guidelines for the management of systolic HF after hospitalization recommend at least a follow-up visit by a cardiologist to adapt treatment according to the New York Heart Association stage, BNP assay in the presence of a suspicion of decompensation and echocardiography in the presence of symptoms or deterioration [10] . Early medical management after discharge from hospital and regular follow-up by a cardiologist have been identified as factors associated with a lower readmission rate [30, 31] .
Mortality and readmission
There is an ongoing debate concerning the impact of early discharge from hospital, as the reduction in mean length of hospital stay could result in higher early mortality and 30-day readmission rates [7] . In 2008, the mean length of hospital stay for HF in France was 9.9 days, higher than the mean stay of 9.2 days in our study, which was limited to first hospitalizations [6] . For comparison, the mean length of hospital stay for all patients with HF is shorter in the USA than in France (8.8 days in 1993 and 6.3 days in 2006) and is tending to decline [20] .
The hospital mortality rate was 6.4% in our study vs. 7.5% in the study on all hospitalizations for HF in France in 2008 [6] . A similar hospital mortality rate of 6.7% was observed in the European EuroHeart Survey II, comprising a younger survey population (mean age 70 years vs. 77 years in our study) with a median length of stay of 9 days [31] . In the USA, the hospital mortality rate decreased from 8.5% in 1993 to 4.3% in 2006 among Medicare beneficiaries [32] . However, the 30-day post-hospital mortality rate, although it also decreased from 17% to 13%, was higher than that reported in our study (11%), which was limited to incident cases of hospitalization. Thirty-day all-cause and HF readmission rates in our study were 18% and 5.1%, respectively. The 2008 national study reported a 20% readmission rate for HF during the first year and 75% of these readmissions occurred during the first 3 months after discharge [6] . Similar 30-day all-cause and HF readmission rates of 22% and 6.1% were reported in veterans covered by Medicare in 2008 in the USA [7] .
Strengths and limitations
On the basis of available data, this study tried to identify and give the characteristics of the first hospitalizations for HF in France. The possibility of first hospitalizations before 2006 (i.e. > 3 years before the inclusion period of this study) cannot be eliminated. One-year and 5-year mortality rates of 20-30% and 45-60%, respectively, have been reported [1] . The bias is therefore limited. Certain groups of the French population were not included in this study due to their occupation, such as civil servants, liberal professionals and farmers, as they are covered by other health insurance schemes. These groups may differ in terms of their age structure and other sociodemographic characteristics, their exposures and their management and access to healthcare. Institutionalized subjects (e.g. in an Établisse-ment d'Hébergement pour Personnes Âgées Dépendantes [EHPAD; accommodation facility for dependent elderly]) were not included in this analysis, especially concerning their individual medicinal product consumption, which is included in the accommodation costs. The data used in this study were derived from medical and administrative databases that collect only limited clinical information, such as those necessary for the distinction between systolic and diastolic HF, which is one of the major limitations of this study. These databases also have the classical limitations concerning the validity of data collection and data coding, such as coding of diagnoses and chronic disease. Estimation of chronic disease status using ALD could be underestimated because the 100% reimbursement of healthcare expenditure is not useful for institutionalized people, those with mutual insurance or those with a preexisting ALD. Some frequencies could be underestimated, especially for laboratory assays performed in public hospitals, or reimbursement of certain medicinal products when they are dispensed during a stay in an institution.
Conclusion
This study revealed a high incidence of first hospitalization for HF, especially among very elderly patients presenting high rates of co-morbidity. The study also demonstrated a high mortality rate and a high early readmission rate. Finally, despite the limitations of the databases used for this study, there still appears to be room for improvement in the drug treatment prescribed on discharge, in terms of frequency and combination therapies, in order to lower the readmission rate. As mentioned in the introduction, disease management programmes have been demonstrated to be effective in many trials, in terms of readmission rates and quality of life, and are therefore now included in clinical practice guidelines. The French national health insurance fund (CNAMTS) is currently developing a return-home and follow-up management programme (PRADO) for patients hospitalized for HF in partnership with general practitioners.
